PMBS News 0.0037 Puramed Bioscience (PMBS)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Puramed Bioscience (PMBS) 0.0037 $PMBS

PuraMed BioScience announces development of its first cannabinoid-based medicine in mental health
M2 - Thu Apr 10, 6:11AM CDT
Healthcare company PuraMed BioScience (Other OTCMBS) said on Wednesday that it plans to develop its first cannabinoid-based formulation that targets the mental health market, with focus on anxiety and depression.

PuraMed BioScience moves forward with the development of its first cannabinoid-based medicine
PR Newswire - Wed Apr 09, 6:25PM CDT
PuraMed BioScience®, Inc. (OTCBB: PMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that the company is moving forward with the development of their first cannabinoid-based formulation that targets the mental health market by focusing on anxiety and depression.

PuraMed BioScience Explores the Development of Hemp and THC-Free Cannabis Formulations to Expand Its Product Line
PRWeb - Mon Mar 24, 6:09AM CDT
PuraMed BioScience(R), Inc., (OTCBBMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, confirmed today that it is seriously exploring the development of cannabinoid and hemp-based formulations to expand its natural and homeopathic product line.

Energy Utilities Focus on Providing Reliable and Safe Service while Meeting Compliance Standards
PR Newswire - Wed Feb 26, 7:00AM CST
To streamline and standardize gas compliance processes and adapt to the demands of the energy service and delivery industry, Ameren Corporation has turned to the mobile workforce management market leader, ClickSoftware Technologies Ltd. (NasdaqGS: CKSW). The implementation of ClickSoftware's scheduling and mobility offering for gas compliance processes will eliminate paper inspection forms and improve data quality, improve flexibility to adapt to rapidly changing regulatory requirements, and provide management with greater visibility into compliance activities.

Merger Approval, Financial Results, Conference Call Schedule, and Stock Price Updates - Research Report on Omnicom, Global Payments, FleetCor, Interpublic, and Fiserv
PR Newswire - Wed Jan 15, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.

LipiGesic M stands alone among over-the-counter migraine medications based on recently released American Headache Society recommendations
PR Newswire - Fri Nov 29, 8:00AM CST
PuraMed BioScience®, Inc., (OTCBBMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that its product, LipiGesic® M does not contain caffeine, acetaminophen, or aspirin. It is the only clinically tested, non-prescription migraine medication available on retail shelves today that has shown no evidence of rebound or "medication overuse headache" as a reported side effect.

PuraMed BioScience Invited to Discuss LipiGesic M on Armed Forces Network
PR Newswire - Thu Aug 29, 11:03AM CDT
PuraMed BioScience®, Inc., (OTCBBMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced that it will discuss LipiGesic M on Armed Forces Network.

PuraMed BioScience Sponsors Miles for Migraine Race with LipiGesic M
PR Newswire - Thu Aug 22, 7:00AM CDT
PuraMed BioScience®, Inc., (OTCBBMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that it will sponsor the 5th Miles for Migraine Race San Francisco by supplying $5,000 of LipiGesic M for the participants.

PuraMed BioScience Inc signs LipiGesic M distributor agreement with OuterBanks Outdoors
M2 - Thu Aug 15, 10:13AM CDT
Healthcare company PuraMed BioScience Inc (OTC BBMBS) reported on Wednesday the launch of an exclusive distribution agreement to sell LipiGesic M on Amazon.com..

PuraMed BioScience Announces Distributor Agreement with OuterBanks Outdoors
PR Newswire - Wed Aug 14, 1:08PM CDT
PuraMed BioScience®, Inc., (OTCBBMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that it has entered into an exclusive distribution agreement with OuterBanks Outdoors to sell LipiGesic® M, its homeopathic formulation of feverfew and ginger for treatment of acute migraine, on Amazon.com.

LipiGesic M is the only recommended first-line therapy for acute migraine that has no evidence of rebound headache
PR Newswire - Mon Aug 05, 2:44PM CDT
PuraMed BioScience®, Inc., (OTCBBMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, confirmed today that its product, LipiGesic® M, a homeopathic formulation of feverfew and ginger that eliminates migraine pain and associated symptoms, is the only recommended first-line therapy for acute migraine in the retail market today that has shown no evidence of rebound or medication-overuse headache.

PuraMed BioScience Inc reports 42.6m outstanding shares in issue
M2 - Wed Jul 03, 4:36AM CDT
Medicinal products company PuraMed BioScience Inc (OTC BBMBS) declared on Tuesday that its current common shares issued and outstanding totalled 42,610,297 as of 30 June 2013.

PuraMed BioScience Announces Common Shares Outstanding of 42.6 Million
PR Newswire - Tue Jul 02, 10:27AM CDT
PuraMed BioScience®, Inc., (OTCBB: PMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announces update of current share structure.

PuraMed BioScience® Announces Science Behind LipiGesic® M Migraine Treatment
PR Newswire - Fri Jun 21, 10:05AM CDT
PuraMed BioScience®, Inc., (OTCBBMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced the science behind LipiGesic® M, its homeopathic, over-the-counter migraine medication.

PuraMed BioScience® Announces Interview on Big Biz Show Discussing LipiGesic® M
PR Newswire - Mon Jun 10, 7:00AM CDT
PuraMed BioScience®, Inc., (OTCBBMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced an interview conducted on Big Biz Show with PuraMed BioScience's CEO Russ Mitchell to discuss and inform listeners about PuraMed BioScience's flagship product, LipiGesic® M.

PuraMed BioScience Discusses Potential for Patent Portfolio Acquisition
PR Newswire - Thu May 30, 10:11AM CDT
PuraMed BioScience®, Inc., (OTCBBMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced an online interview to discuss recent developments, and the potential acquisition of a health and beauty products patent portfolio.

PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756
PR Newswire - Thu May 23, 1:10PM CDT
PuraMed BioScience®, Inc., (OTCBB: PMBS) a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced that Ludlow Research re-issued its research opinion on the company based on low market capitalization valuation.

LipiGesic® M Migraine Treatment Product Shown to be as Effective as Prescription Based Medications
PR Newswire - Tue May 21, 1:33PM CDT
PuraMed BioScience®, Inc., (OTCBBMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced the results of clinical trials that found its over-the-counter migraine medication product, LipiGesic® M, has "robust efficacy".

PuraMed BioScience®, Inc., Launches Its Business-to-Business Migraine First Aid Kit(TM) to Promote Workplace Health and Wellness
PR Newswire - Wed May 15, 3:01PM CDT
PuraMed BioScience®, Inc., (OTCBB: PMBS) announces the launch of its Business-to-Business Migraine First Aid Kit(TM). The program, which is available to businesses of any size, can help migraine sufferers stay on the job and stay productive by eliminating migraine pain and associated symptoms.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lennar Lawsuit Puts Land-Light Claims Under a Microscope

Updated Category News Views 118

Three ugly selloffs, a murky land-bank story, and a fresh securities complaint have turned Lennar into the sort of holding that makes shareholders reread every footnote. The lawsuit is not a verdict, and the allegations remain unproven, but the timeline is nasty enough that investors in NYSE:LEN should not shrug it off as ordinary housing-cycle turbulence. The Dates...

Continue Reading
V2’s FOAS Bets on Candid Ad Sales Operator Dialogue

Updated Category News Views 180

Ad sales rarely gets fixed by another ballroom panel, and V2 seems to know it. Its new Future of Ad Sales, or FOAS, forum is built around a simpler premise: put senior operators in a small room, keep vendors and conference theatrics out of the way, and let people compare the ugly real-world details of running revenue machines. Announced November 19, 2026, FOAS is an...

Continue Reading
Vail Resorts Bets on Music to Deepen Epic Pass Demand

Updated Category News Views 119

A bass drop at 11,000 feet is not merely a party trick when you run 42 mountain resorts. Vail Resorts is putting live music, après programming and destination events squarely beside skiing and riding for winter 2026-27, and the business logic is pretty plain: give people another reason to buy early, stay longer and return with friends. For investors watching MTN, this is...

Continue Reading
BreakBio's New CSO Adds Vaccine Trial Credibility in Cancer

Updated Category News Views 144

Personalized cancer vaccines have no shortage of grand promises; seasoned clinical operators are the rarer commodity. That is why BreakBio's appointment of Dr. Greg Lizée as chief scientific officer deserves a closer look, even if nobody should confuse an executive hire with clinical validation. BreakBio is private, its lead program remains in development, and cancer...

Continue Reading
Huhtamaki Maps Its 2027 Reporting Dates for Investors

Updated Category News Views 17

A calendar release rarely makes the pulse race, but it tells shareholders when the curtain will actually go up. Huhtamäki Oyj has laid out its 2027 financial reporting timetable, and the useful part is its plainness: investors now know the handful of dates when management will have to put numbers, not broad ambitions, in front of the market. For a packaging company, that...

Continue Reading
Siteimprove Turns Accessibility Checks Into Agent Spend

Updated Category News Views 153

Accessibility work has usually been the thing teams promise to fix after the launch party is over. Siteimprove is trying to shove that discipline directly into the AI-agent workflow, announcing on November 19, 2026 that its Siteimprove.ai Accessibility Agent is available through Agentic Commerce on AWS Marketplace. The practical hook is simple enough: an AI agent can...

Continue Reading
Hard Rock Tampa Bets $30 Million on Smoke-Free Play

Updated Category News Views 71

Cigarette smoke is getting treated like a revenue problem in Tampa, and that is a far more interesting signal than another ribbon-cutting photo. Seminole Hard Rock Hotel & Casino Tampa opened The Breeze: A Smoke-Free Experience by Hard Rock on Nov. 19, 2026, following a $30 million transformation aimed at guests who want clean-air casino time from arrival through...

Continue Reading
Colossal's Halloween Campaign Wins Top Communicator Honor

Updated Category News Views 76

A horror-themed fan competition putting money toward hospitalized children is not the usual awards-season material, which is precisely why Colossal's latest recognition lands with some weight. The Phoenix-based professional fundraiser received an Award of Excellence, the top honor at the 32nd annual Communicator Awards, for its Face of Halloween campaign in the Innovation...

Continue Reading
Makera A1S Tests the Desktop CNC Metal-Cutting Promise

Updated Category News Views 84

Aluminum chips are where desktop-machine marketing stops bluffing, and Makera is leaning right into that test with the A1S. The company opened global pre-orders on November 18 for a machine aimed squarely at the awkward middle ground: users who have outgrown entry-level hobby gear but do not have room, budget, or patience for a full industrial setup. That is a real market...

Continue Reading
Genome-Written XDP Mice Could Sharpen Drug Research

Updated Category News Views 88

Seventy-eight thousand DNA letters changed the pace of a cruel little-known disease story. NYU Langone researchers inserted a human disease-linked stretch of genetic material into mice and produced an accelerated model of X-linked dystonia-parkinsonism, or XDP. That is a serious laboratory accomplishment, not a cure announcement, and it deserves to be read with both...

Continue Reading

Top 5 Most Recently Viewed Articles

Canada Nickel Secures EDC Interest for $500 Million Financing

Updated Category News Views 137

Canada Nickel's Significant Financing Achievement Canada Nickel Company Inc. is excited to share a major milestone in its efforts to secure financing for the Crawford Nickel Sulphide Project. The company has received a Letter of Interest (LOI) from Export Development Canada (EDC), indicating its intention to offer up to US$500 million in long-term debt financing for the...

Continue Reading
BlackRock Expands Offerings with New ETF Share Class Approval

Updated Category News Views 202

BlackRock Pursues SEC Approval for ETF Share Classes BlackRock Inc (NYSE: BLK) is making headlines as it has formally applied to the U.S. Securities and Exchange Commission (SEC) for a ruling that would allow the establishment of exchange-traded fund (ETF) share classes linked to its existing mutual funds. This significant move positions BlackRock as the largest firm...

Continue Reading
Profusa Unveils Innovative AI Portal for Continuous Biochemistry Monitoring

Updated Category News Views 133

Profusa Introduces AI-Powered Insight Portal for Biomarker Monitoring Profusa, a pioneering company in digital health technology, is transforming how healthcare providers monitor patient biochemistry through an innovative AI-driven insight portal. This advanced portal will enhance continuous biomarker tracking, utilizing cutting-edge technology to provide clinical...

Continue Reading
Investigation Launch for Pliant Therapeutics Investors: What to Know

Updated Category News Views 192

Investigation of Pliant Therapeutics, Inc. Pliant Therapeutics, Inc. (NASDAQ: PLRX) is currently under scrutiny as investors seek clarity on potential securities law violations. This investigation presents an opportunity for shareholders who believe they have been misled regarding their investments. Shareholders are encouraged to come forward to ensure their rights are...

Continue Reading
Fish Window Cleaning's New Headquarters: A Step Forward in Growth

Updated Category News Views 2161

Fish Window Cleaning Unveils New Corporate Headquarters Fish Window Cleaning Services is excited to announce the grand opening of its brand-new corporate headquarters, a facility that signifies an important milestone in its growth and operational capabilities. Located at 217 Chesterfield Towne Centre, this expansive 12,500-square-foot space is intended to serve as the...

Continue Reading